Wang et al. also suggest that somatostatin could be used in diagnostic tests to detect abnormal levels of oligomeric Aβ in the brain or body fluids of people who have Alzheimer’s disease. Here, SST is linked to early-onset autosomal dominant Alzheimer disease.